Campaign Against Woodcock’s US FDA Commissioner Bid Has Begun

Opioid issues delayed Robert Califf’s confirmation as FDA commissioner. Could they prevent the nomination of Janet Woodcock?

Janet Woodcock and Joshua Sharfstein are the leading contenders for FDA commissioner. (Credit: Alex Wong/Getty Images; Mark Wilson/Getty Images)
Joshua Sharfstein and Janet Woodcock are the leading contenders to be nominated for FDA commissioner. • Source: Alex Wong and Mark Wilson/Getty Images

The US Food and Drug Administration action’s, or lack thereof, on the opioid epidemic once again could influence a commissioner confirmation fight.

A group of 30 organizations, including several involved in fighting the opioid pandemic, outlined their “strong opposition” to acting FDA Commissioner Janet Woodcock becoming President Biden’s nominee for the permanent position in a 27 January

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

More from Agency Leadership